Certified by Founder Lodge
CellCentric
United Kingdom - Cambridge
START UP
1 Disclosed Funding Rounds $25,000,000
0 Participating Investments
-
Founded date
2004
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally.
p300/CBP are twin (paralogue) acetyl transferases
Pfizer
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
Distribusion Technologies | $80,000,000 | (Sep 27, 2024)
Quorum | Undisclosed Amount | (Sep 27, 2024)
Convergence | $12,000,000 | (Sep 27, 2024)
Tetrix | $5,000,000 | (Sep 27, 2024)
AmpUp | $15,000,000 | (Sep 27, 2024)
